Hepion Pharmaceuticals, Inc. financial data

Symbol
HEPA on Nasdaq, CTRVP on OTC
Industry
Pharmaceutical Preparations
Location
399 Thornall Street, First Floor, Edison, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
ContraVir Pharmaceuticals, Inc. (to 7/23/2019)
Latest financial report
10-K - Q4 2024 - Apr 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 277 % -31.2%
Debt-to-equity 210 % +334%
Return On Equity -599 % -166%
Return On Assets -193 % -27.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11M shares +101%
Common Stock, Shares, Outstanding 139K shares +44.4%
Entity Public Float 5.9M USD -85.4%
Common Stock, Value, Issued 14 USD +40%
Weighted Average Number of Shares Outstanding, Basic 123K shares +54.7%
Weighted Average Number of Shares Outstanding, Diluted 123K shares +54.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 11.8M USD -66.8%
General and Administrative Expense 7.5M USD -22%
Operating Income (Loss) -19.3M USD +60.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.2M USD +67.2%
Income Tax Expense (Benefit) -3.38M USD -17.1%
Net Income (Loss) Attributable to Parent -13.2M USD +73%
Earnings Per Share, Basic -107 USD/shares +82.6%
Earnings Per Share, Diluted -107 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 1.61M USD -90.8%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 118K USD -51.2%
Other Assets, Noncurrent 66.5K USD
Assets 1.61M USD -91.1%
Accounts Payable, Current 220K USD -90.6%
Employee-related Liabilities, Current 0 USD -100%
Accrued Liabilities, Current 23.7K USD -99%
Liabilities, Current 3.14M USD -40.6%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 41.2K USD
Liabilities 3.48M USD -67.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8.35K USD
Retained Earnings (Accumulated Deficit) -238M USD -5.87%
Stockholders' Equity Attributable to Parent -1.86M USD -126%
Liabilities and Equity 1.61M USD -91.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.62M USD +56%
Net Cash Provided by (Used in) Financing Activities 1.85M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 139K shares +44.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.68M USD +79.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 406K USD -97.3%
Deferred Tax Assets, Valuation Allowance 44.6M USD +0.09%
Deferred Tax Assets, Gross 44.6M USD -0.05%
Operating Lease, Liability 118K USD -51.2%
Depreciation 100K USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -13.1M USD +73.2%
Lessee, Operating Lease, Liability, to be Paid 139K USD -46.9%
Operating Lease, Liability, Current 118K USD +5.05%
Lessee, Operating Lease, Liability, to be Paid, Year Two 97.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 97.8K USD -28.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +123%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.3K USD +2.97%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Additional Paid in Capital 234M USD +1.72%
Depreciation, Depletion and Amortization 30.8K USD +70.5%
Deferred Tax Assets, Net of Valuation Allowance 62.5K USD -88.9%
Share-based Payment Arrangement, Expense 792K USD -67.2%
Interest Expense 11.5K USD +11.8%